Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.
Humans
Female
Male
Melanoma
/ drug therapy
Carboplatin
/ administration & dosage
Paclitaxel
/ therapeutic use
Retrospective Studies
Middle Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Aged
Adult
Drug Resistance, Neoplasm
Immune Checkpoint Inhibitors
/ therapeutic use
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Skin Neoplasms
/ drug therapy
Aged, 80 and over
Immunoresistance
Melanoma
Palliative treatment
Platinum-based chemotherapy
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
received:
05
08
2024
accepted:
18
09
2024
medline:
2
10
2024
pubmed:
2
10
2024
entrez:
1
10
2024
Statut:
epublish
Résumé
Immunotherapy with anti-PD-1 antibodies significantly improved the prognosis in advanced melanoma patients, but most of them develop primary or secondary resistance to the treatment. In this study, we evaluated efficacy and safety of a chemotherapy regimen with weekly carboplatin plus paclitaxel (wCP) in patients previously treated with anti-PD-1 antibodies. We retrospectively identified 30 patients with advanced melanoma treated at our Institute over the last eight years with wCP. The co-primary endpoints of the study were overall survival (OS) and progression-free survival (PFS). In addition, we evaluated treatment tolerability. For this patient cohort, median PFS and OS were 3.25 and 7.69 months, respectively. All included patients had previously received anti-PD-1 immunotherapy, most of them had ECOG PS 0-1, and only 5 patients had a BRAF V600 mutation. In univariable analysis, we observed shorter OS in patients with > 2 involved metastatic sites, superficial spreading histology, and serum lactate dehydrogenase (LDH) values above the median. Liver metastases were associated with worse outcomes, while radiotherapy treatment of brain metastases was associated with improved OS. However, in a multivariable Cox regression model, only LDH above the median, superficial spreading histology, and female sex were significantly associated with worse OS. We reported grade 3 and 4 treatment-related toxicities in 4 and 0 patients, respectively. In conclusion, chemotherapy with wCP is a valid palliative treatment in advanced melanoma who progressed with anti-PD-1 antibodies.
Identifiants
pubmed: 39354418
doi: 10.1186/s12885-024-12961-9
pii: 10.1186/s12885-024-12961-9
doi:
Substances chimiques
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Immune Checkpoint Inhibitors
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1220Subventions
Organisme : Italian Ministry of Health, Ricerca Corrente
ID : RC2022-2024
Organisme : Italian Ministry of Health, Ricerca Corrente
ID : RC2022-2024
Organisme : Italian Ministry of Health, Ricerca Corrente
ID : RC2022-2024
Informations de copyright
© 2024. The Author(s).
Références
Lao CD, Khushalani NI, Angeles C, Petrella TM. Current state of adjuvant therapy for Melanoma: less is more, or more is better? Am Soc Clin Oncol Educ book Am Soc Clin Oncol Annu Meet. 2022;42:738–44.
doi: 10.1200/EDBK_351153
Hassel JC, Zimmer L, Sickmann T, Eigentler TK, Meier F, Mohr P, et al. Medical needs and therapeutic options for Melanoma patients resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers (Basel). 2023;15:3448.
doi: 10.3390/cancers15133448
pubmed: 37444558
Vera Aguilera J, Paludo J, Mcwilliams RR, Zhang H, Li Y, Kumar AB, et al. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res. 2020;30:364–75.
doi: 10.1097/CMR.0000000000000669
pubmed: 32404734
pmcid: 7331824
Goldinger SM, Buder-Bakhaya K, Lo SN, Forschner A, McKean M, Zimmer L, et al. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. Eur J Cancer. 2022;162:22–33.
doi: 10.1016/j.ejca.2021.11.022
pubmed: 34952480
Klee G, Hagelstein V, Kurzhals JK, Zillikens D, Terheyden P, Langan EA. Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete? Melanoma Res. 2022;32:360–5.
doi: 10.1097/CMR.0000000000000844
pubmed: 35855658
Maeda T, Yoshino K, Nagai K, Oaku S, Kato M, Hiura A, et al. The efficacy of platinum-based chemotherapy for immune checkpoint inhibitor-resistant advanced melanoma. Acta Oncol. 2019;58:379–81.
doi: 10.1080/0284186X.2018.1541252
pubmed: 30614355
Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26.
doi: 10.1056/NEJMoa1104621
pubmed: 21639810
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Zimpfer-Rechner C, Hofmann U, Figl R, Becker JC, Trefzer U, Keller I, et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res. 2003;13:531–6.
doi: 10.1097/00008390-200310000-00012
pubmed: 14512795
Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006;106:375–82.
doi: 10.1002/cncr.21611
pubmed: 16342250
Arance A, de la Cruz-Merino L, Petrella TM, Jamal R, Ny L, Carneiro A, Berrocal A, et al. Phase II LEAP-004 study of Lenvatinib Plus Pembrolizumab for melanoma with confirmed progression on a programmed cell death Protein-1 or programmed death Ligand 1 inhibitor given as monotherapy or in combination. J Clin Oncol. 2023;41:75–85.
doi: 10.1200/JCO.22.00221
pubmed: 35867951
Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, et al. Nivolumab and Relatlimab in patients with advanced melanoma that had progressed on Anti-programmed Death-1/Programmed death Ligand 1 therapy: results from the phase I/IIa RELATIVITY-020 trial. J Clin Oncol. 2023;41:2724–35.
doi: 10.1200/JCO.22.02072
pubmed: 36780608
pmcid: 10431305
Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:435–45.
doi: 10.1016/S1470-2045(17)30180-8
pubmed: 28284557
Park SE, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Increased response rates to Salvage Chemotherapy Administered after PD-1/PD-L1 inhibitors in patients with Non-small Cell Lung Cancer. J Thorac Oncol. 2018;13:106–11.
doi: 10.1016/j.jtho.2017.10.011
pubmed: 29101058
Szabados B, van Dijk N, Tang YZ, van der Heijden MS, Wimalasingham A, Gomez de Liano A, et al. Response rate to Chemotherapy after Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. Eur Urol. 2018;73:149–52.
doi: 10.1016/j.eururo.2017.08.022
pubmed: 28917596
Zheng H, Zeltsman M, Zauderer MG, Eguchi T, Vaghjiani RG, Adusumilli PS. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. Immunotherapy. 2017;9:913–27.
doi: 10.2217/imt-2017-0052
pubmed: 29338609
pmcid: 5810850
Cona MS, Lecchi M, Cresta S, Damian S, Del Vecchio M, Necchi A et al. Combination of baseline LDH, performance status and age as Integrated Algorithm to identify solid Tumor patients with higher probability of response to anti PD-1 and PD-L1 monoclonal antibodies. Cancers (Basel). 2019;11.
Di Pietro FR, Verkhovskaia S, Mastroeni S, Carbone ML, Abeni D, Di Rocco CZ et al. Clinical predictors of response to Anti-PD-1 First-Line treatment in a single-centre patient cohort: a real-world study. Clin Oncol (R Coll Radiol). 2022;34:e18–24.
Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res. 2017;5:417–24.
doi: 10.1158/2326-6066.CIR-16-0325
pubmed: 28411193
pmcid: 5749922
Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the brain. N Engl J Med. 2018;379:722–30.
doi: 10.1056/NEJMoa1805453
pubmed: 30134131
pmcid: 8011001
Manacorda S, Carmena MDT, Malone C, Linh Le HM, Furness AJS, Larkin J, et al. Ipilimumab plus Nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids. Eur J Cancer. 2023;188:98–107.
doi: 10.1016/j.ejca.2023.04.018
pubmed: 37229837
Falcone R, Verkhovskaia S, Di Pietro FR, Poti G, Samela T, Carbone ML, et al. Primary mucosal melanoma: clinical experience from a single Italian center. Curr Oncol. 2024;31:588–97.
doi: 10.3390/curroncol31010042
pubmed: 38275835
pmcid: 10814710
Botticelli A, Cirillo A, Scagnoli S, Cerbelli B, Strigari L, Cortellini A et al. The agnostic role of site of Metastasis in Predicting outcomes in Cancer patients treated with immunotherapy. Vaccines. 2020;8.